Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PGL8 | ISIN: US14817C1071 | Ticker-Symbol: PX91
Tradegate
28.03.24
19:58 Uhr
18,725 Euro
-0,070
-0,37 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CASSAVA SCIENCES INC Chart 1 Jahr
5-Tage-Chart
CASSAVA SCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
18,50019,08028.03.
18,51019,08028.03.

Aktuelle News zur CASSAVA SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoCassava Sciences, Inc.: Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials206An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials...
► Artikel lesen
21.03.(SAVA) - Analyzing Cassava Sciences' Short Interest8
12.03.Cassava Sciences under scrutiny following a damaging FDA report32
12.03.Cassava Sciences again under scrutiny over Alzheimer's drug research30
04.03.Cassava Sciences, Inc.: Cassava Sciences Announces Virtual Presentation at the AD/PD 2024 International Conference28
28.02.CASSAVA SCIENCES INC - 10-K, Annual Report5
28.02.Cassava Sciences Inc reports results for the quarter ended in December - Earnings Summary7
28.02.Cassava Sciences GAAP EPS of -$0.509
28.02.CASSAVA SCIENCES INC - 8-K, Current Report3
28.02.Cassava Sciences, Inc.: Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates246$121.1 Million In Cash and Cash Equivalents at December 31, 2023, With an Additional $21.8 Million Raised In 2024 From Exercise of Warrants.A Total of Over 555 Study Participants Have Completed Our...
► Artikel lesen
08.02.Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial18
07.02.Why Alzheimers-Drug Developer Cassava Sciences Stock Is Trending15
07.02.CASSAVA SCIENCES INC - 8-K, Current Report4
07.02.Cassava Sciences, Inc.: No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months7
03.02.Is There Any Hope for Cassava Sciences Stock?11
29.01.(SAVA) - Analyzing Cassava Sciences' Short Interest9
18.01.Cassava Sciences (SAVA) stock: Is it a buy as short-squeeze eases?24
16.01.Cassava Sciences Stock Continues Showing Rising Relative Strength9
05.01.New SAVAW Warrants Are Trading After Cassava Sciences' Distribution24
05.01.Cassava Sciences finalizes distribution of warrants for stock purchase18
Seite:  Weiter >>
58 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
4,2,8